Systemische Krankheitsmanifestationen und Komorbidität bei rheumatoider Arthritis

S. Kleinert; U. Müller-Ladner; M. Englbrecht

doi:10.1055/s-0037-1618129

Arthritis und Rheuma, Table of Contents

Arthritis und Rheuma 2012; 32(04): 223-231
DOI: 10.1055/s-0037-1618129

Rheumatoide Arthritis 2012 – alles neu?

Schattauer GmbH

Systemische Krankheitsmanifestationen und Komorbidität bei rheumatoider Arthritis

Kardiovaskuläres Risiko und DepressionSystemic manifestations of disease and comorbidities: cardiovascular risk and depression in patients with rheumatoid arthritisCardiovascular risk and depression

S. Kleinert

¹Rheumatologische Schwerpunktpraxis Erlangen

,

U. Müller-Ladner

²Justus-Liebig Universität Gießen, Abt. Rheumatologie und Klinische Immunologie, Kerckhoff-Klinik Bad Nauheim

,

M. Englbrecht

³Medizinische Klinik 3 (Rheumatologie & Immunologie), Universitätsklinikum Erlangen

› Author Affiliations

Abstract

Zusammenfassung

Die rheumatoide Arthritis wird zunehmend als Systemerkrankung betrachtet. Systemische Manifestationen und Komorbidität wie kardiovaskuläres Risiko, Malignom- bzw. Lymphomrisiko, Fatigue und Depression, Anämie, Osteoporose und Dyslipid ämie geraten immer mehr in den Blickpunkt. Zwischen dem Ausmaß der Gelenkzerstörung und dem Vorhandensein einer Depression besteht nicht unbedingt ein Zusammenhang. Die Symptome der Depression können sich mit Symptomen der Erkrankung wie allgemeine Müdigkeit, Erschöpfungszustände oder verminderte Schlafqualität überlappen. Bezüglich des kardiovaskulären Risikos sollte bei RA-Patienten eine jährliche Risikoeinschätzung nach den Empfehlungen der Fachgesellschaften erfolgen. Dabei ist das krankheitsspezifische kardiovaskuläre Risiko abhängig von der Höhe der entzündlichen Aktivität über die Zeit.

Summary

Rheumatoid arthritis is considered more and more as a systemic disease rather than a pure joint disease. Epidemiologic studies focus increasingly on systemic disease manifestations and comorbidities, e. g. cardiovascular risk, lymphoma, fatigue and depression, anemia, osteoporosis and dyslipidemia. The extent of joint destruction does not correlate with the prevalence of depression. Symptoms of depression need to be differentiated from symptoms of disease, i. e. fatigue or reduced sleeping quality. An annual risk assessment is recommended by the respective professional societies as RA-specific cardiovascular risk depends on the amount of inflammation over time.

Schlüsselwörter

Rheumatoide Arthritis - Depression - kardiovaskuläre Erkrankung - kardiovaskuläres Risiko - Komorbidität

Keywords

Rheumatoid arthritis - depression - cardiovascular diseases - cardiovascular riks - comorbidity

Full Text

References

Literatur
1 Smolen JS. et al. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis 2010; 69 (04) 631-637.
2 Covic T. et al. Variability in depression prevalence in early rheumatoid arthritis: a comparison of the CES-D and HAD-D Scales. BMC Musculoskelet Disord 2009; 10: 18.
3 Dickens C. et al. Depression in rheumatoid arthritis: a systematic review of the literature with metaanalysis. Psychosom Med 2002; 64 (01) 52-60.
4 Isik A. et al. Anxiety and depression in patients with rheumatoid arthritis. Clin Rheumatol 2007; 26 (06) 872-878.
5 Katz PP, Yelin EH. Prevalence and correlates of depressive symptoms among persons with rheumatoid arthritis. J Rheumatol 1993; 20 (05) 790-796.
6 Tekaya R. et al. Assessment of depression in rheumatoid arthritis: A cross sectional study on 60 patients. Presse Med. 2012 Jan 24.
7 DiMatteo MR. et al. Depression is a risk factor for noncompliance with medical treatment: metaanalysis of the effects of anxiety and depression on patient adherence. Arch Intern Med 2000; 160 (14) 2101-2107.
8 Zyrianova Y. et al. Depression and anxiety in rheumatoid arthritis: the role of perceived social support. Ir J Med Sci 2006; 175 (02) 32-36.
9 Covic T. et al. Depression in rheumatoid arthritis patients: demographic, clinical, and psychological predictors. J Psychosom Res 2006; 60 (05) 469-476.
10 Beck AT. Depression: Clinical, experimental and theoretical aspects. New York: Harper & Row; 1967
11 Beck AT. Cognitive models of depression. J Cogn Psychother: An Int Quarterly 1987; 1: 5-37.
12 Seligman ME. et al. Learned helplessness in the rat: time course, immunization, and reversibility. J Comp Physiol Psychol 1975; 88 (02) 542-547.
13 Abramson LY. et al. Learned helplessness in humans: critique and reformulation. J Abnorm Psychol 1978; 87 (01) 49-74.
14 Pincus T, Callahan LF. Depression scales in rheumatoid arthritis: criterion contamination in interpretation of patient responses. Patient Educ Couns 1993; 20 (2–3): 133-143.
15 Pincus T. et al. Criterion contamination of depression scales in patients with rheumatoid arthritis: the need for interpretation of patient questionnaires (as all clinical measures) in the context of all information about the patient. Rheum Dis Clin North Am 2009; 35 (04) 861-864 xi-xii.
16 Beck AT. et al. An inventory for measuring depression. Archives of general psychiatry 1961; 4: 561-571.
17 Beck AT. et al. Beck Depression Inventory. 2nd ed.. San Antonio: The Psychological Corporation; 1996
18 Hautzinger M. et al. C. BDI II – Beck DepressionsInventar – Manual. Frankfurt a. M.: Harcourt Test Services; 2006
19 Lowe B. et al. Comparative validity of three screening questionnaires for DSM-IV depressive disorders and physicians’ diagnoses. Journal of affective disorders 2004; 78 (02) 131-140.
20 Spitzer RL. et al. Validation and utility of a self-report version of PRIME-MD: the PHQ primary care study. Primary Care Evaluation of Mental Disorders. Patient Health Questionnaire. JAMA 1999; 282 (18) 1737-1744.
21 Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. The British journal of psychiatry: the journal of mental science 1979; 134: 382-389.
22 Neumann HU, Schulte RM. Montgomery-AsbergDepressions-Rating-Skala. Bestimmung der Validität und Interrater-Reliabilität der deuschen Fassung. Psycho 1988; 14 (12) 911-924.
23 Parker JC. et al. Management of depression in rheumatoid arthritis: a combined pharmacologic and cognitive-behavioral approach. Arthritis Rheum 2003; 49 (06) 766-777.
24 Keefe FJ, Caldwell DS. Cognitive behavioral control of arthritis pain. Med Clin North Am 1997; 81 (01) 277-290.
25 Parker JC. et al. Pain management in rheumatoid arthritis patients. A cognitive-behavioral approach. Arthritis Rheum 1988; 31 (05) 593-601.
26 Parker JC. et al. Pain control and rational thinking. Implications for rheumatoid arthritis. Arthritis Rheum 1989; 32 (08) 984-990.
27 Keefe FJ. et al. Coping with rheumatoid arthritis pain: catastro phizing as a maladaptive strategy. Pain 1989; 37 (01) 51-56.
28 Keefe FJ. et al. Pain coping strategies and coping efficacy in rheumatoid arthritis: a daily process analysis. Pain 1997; 69 (1–2): 35-42.
29 Keefe FJ. et al. Analyzing pain in rheumatoid arthritis patients. Pain coping strategies in patients who have had knee replacement surgery. Pain 1991; 46 (02) 153-160.
30 Newman SP, Revenson TA. Coping with rheumatoid arthritis. Baillieres Clin Rheumatol 1993; 7 (02) 259-280.
31 Newth S, DeLongis A. Individual differences, mood, and coping with chronic pain in rheumatoid arthritis: A daily process analysis. Psychology and Health 2004; 19 (03) 283-305.
32 Buckelew SP, Parker JC. Coping with arthritis pain. A review of the literature. Arthritis Care Res 1989; 2 (04) 136-145.
33 Penninx BW. et al. Direct and buffer effects of social support and personal coping resources in individuals with arthritis. Soc Sci Med 1997; 44 (03) 393-402.
34 Peters MJ. et al. EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis. Ann Rheum Dis 2010; 69 (02) 325-331.
35 Avina-Zubieta JA. et al. Risk of incident cardiovascular events in patients with rheumatoid arthritis: a meta-analysis of observational studies. Annals of the Rheumatic Diseases. 2012 March 16, 2012.
36 Kerola AM. et al. How early in the course of rheumatoid arthritis does the excess cardiovascular risk appear?. Annals of the Rheumatic Diseases. 2012 June 26, 2012.
37 Innala L. et al. Cardiovascular events in early RA are a result of inflammatory burden and traditional risk factors: a five year prospective study. Arthritis Res Ther 2011; 13 (04) R131.
38 Wolfe F, Michaud K. The risk of myocardial infarction and pharmacologic and nonpharmacologic myocardial infarction predictors in rheumatoid arthritis: a cohort and nested case-control analysis. Arthritis Rheum 2008; 58 (09) 2612-2621.
39 Micha R. et al. Systematic review and meta-analysis of methotrexate use and risk of cardiovascular disease. Am J Cardiol 2011; 108 (09) 1362-1370.
40 Listing J. et al. Successful Control of Disease Activity and Treatment with Biologics increase Life Expectancy in Rheumatoid Arthritis Patients. Ann Rheum Dis 2012; 71 (Suppl. 03) 69.
41 Greenberg JD. et al. Tumour necrosis factor antagonist use and associated risk reduction of cardiovascular events among patients with rheumatoid arthritis. Ann Rheum Dis 2011; 70 (04) 576-582.
42 Dixon WG. et al. Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti-tumor necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum 2007; 56 (09) 2905-2912.
43 Sheng X. et al. Effectiveness of Statins on Total Cholesterol and Cardiovascular Disease and All-cause Mortality in Osteoarthritis and Rheumatoid Arthritis. J Rheumatol 2012; 39 (01) 32-40.
44 Toms TE. et al. Statin use in rheumatoid arthritis in relation to actual cardiovascular risk: evidence for substantial undertreatment of lipid-associated cardiovascular risk?. Ann Rheum Dis 2010; 69 (04) 683-688.
45 Peters MJ. et al. EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis. Ann Rheum Dis. 2009 Sep 22.
46 Cairo MS. al. NCI first International Workshop on the biology, prevention, and treatment of relapse after allogeneic hematopoietic stem cell transplantation: report from the committee on the biological considerations of hematological relapse following allogeneic stem cell transplantation unrelated to graft-versus-tumor effects: state of the science. Biol Blood Marrow Transplant 2010; 16 (06) 709-728.
47 Deutsche Hochdruckliga e. V. DHL®, Gesellschaft DH. Leitlinien zur Behandlung der arteriellen Hypertonie. AWMF Register-Nr. 046/001 2008
48 Deutsche Hochdruckliga e.V. DHL®, Prävention DGfHu. Neue Entwicklungen in der Hochdrucktherapie: Eine Bewertung durch die Deutsche Hochdruckliga e.V. DHL^® Deutsche Gesellschaft für Hypertonie und Prävention. 2011
49 Reiner Z. et al. ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the ESC and the EAS. Eur Heart J 2011; 32 (14) 1769-1818.
50 Keil U. et al. Risikoabschätzung tödlicher HerzKreislauf-Erkrankungen. Deutsches Ärzteblatt 2005; 25: A1808-A1812.